What they were paid
Royalty Pharma Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $68,071 | $314,934 | — | — | $383,005 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Royalty Pharma plc DEF 14A filed April 10, 2026, accession 0001140361-26-014239, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Royalty Pharma pays directors a $150,000 cash retainer and $250,000 in RSUs.
Committees
FY2025 · as the proxy prints themCompensation
The rest of the Royalty Pharma board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Bonnie Bassler, Ph.D | Independent Director | $399,981 |
| Carole Ho, M.D | Independent Director | $383,005 |
| Catherine Engelbert | Independent Director | $399,981 |
| David Hodgson | Independent Director | $399,981 |
| Errol De Souza, Ph.D | Independent Director | $399,981 |
| Gregory Norden | Independent Director | $399,981 |
| Pablo Legorreta | Chair of the Board | $0 |
| Ted Love, M.D | Independent Director | $399,981 |
| Vlad Coric, M.D | Independent Director | $462,000 |
The full Royalty Pharma compensation record
free company briefThis page is one director within Royalty Pharma's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat